Development, Gene Editing, Gene Sequencing and In-Vivo

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). billion in potential milestones if the project advances through development and onto the market. billion agreement that started in 2020.

Gene Editing

Gene Editing In-Vivo Gene Sequencing Gene

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . Vertex is also offering up to $1.3

Gene Editing

Gene Editing Genetics Drugs Gene

Clinical Research Informer

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

Stay Connected